ReviewBritish journal of cancer2023
The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer.
Review in British journal of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The prognostic value of the lung immune prognostic index in patients with urological cancers: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Prognostic significance of the C-reactive protein-to-lymphocyte ratio in patients with cancers.Frontiers in oncology · 2026Pooled it
- Next-generation natural killer cell therapy: bench to bedside and beyond.Signal transduction and targeted therapy · 2026Review
- Review
- Harnessing immunity against breast cancer: from checkpoints to cell therapies.Journal of translational medicine · 2026Review
- Metabolic enzymes and immune receptors as emerging checkpoints in breast cancer: mechanisms, clinical trials, and therapeutic implications.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Integrative Pan-Cancer Mapping of Proteasome Dependency Prioritizes PSMB5 and PSMB6 as Context-Dependent Vulnerability Biomarkers Linked to Immune Context.Molecules (Basel, Switzerland) · 2026Article
- Folic acid-modified antigen-trapping nanoprobes for developing in situ tumor vaccines to inhibit metastasis and recurrence of ovarian cancer.Journal of nanobiotechnology · 2026Article
- GlycA as an Effect Modifier of Protein-Mortality Associations: A Prospective Cohort Study.Clinical and translational science · 2026Article
- The role of PCMT1 in prognosis tumor immune microenvironment and therapeutic responses across cancers.Discover oncology · 2026Article
- Integrative prognostic model incorporating high mobility group box 1 subcellular localization and tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma.Diagnostic pathology · 2025Article
- Impact of physical and psychological stressors on tumor growth and immune responses in breast cancer.Comprehensive psychoneuroendocrinology · 2025Article
- Tumor microenvironment phenotyping guides precision therapy in unresectable pancreatic cancer.World journal of gastrointestinal oncology · 2025Review
- ASO Author Reflections: Precision Immunoprofiling of the Tumor Microenvironment Predicts Recurrence in Advanced Colorectal Cancer.Annals of surgical oncology · 2025Article
- Role of diabetes-related inflammation in pancreatic cancer evaluated by aptamer-based detection of circulating tumor cells in a streptozotocin-induced Panc02-transplanted murine model.Annals of hepato-biliary-pancreatic surgery · 2025Article
- Relationship between aggregate index of systemic inflammation and mortality from CCD and malignant neoplasms in diabetic patients.Scientific reports · 2025Article
- High expression of HECW1 is associated with the poor prognosis and cancer progression of gastric cancer.World journal of surgical oncology · 2025Article
- Clinical and Fundamental Research Progressions on Tumor-Infiltrating Lymphocytes Therapy in Cancer.Vaccines · 2025Review
- The Role of Tregs in the Tumor Microenvironment.Biomedicines · 2025Review
- A panel of cancer testis antigens in squamous cell carcinoma of the lung, head and neck, and esophagus: implication for biomarkers and therapeutic targets.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumour immunotherapy has achieved remarkable clinical success in many different types of cancer in the past two decades. The outcome of immune checkpoint inhibitors in cancer patients has been linked to the quality and magnitude of T cell, NK cell, and more recently, B cell within the tumour microenvironment, suggesting that the immune landscape of a tumour is highly connected to patient response and prognosis. It is critical to understanding tumour immune microenvironments for identifying immune modifiers of cancer progression and developing cancer immunotherapies. The infiltration of solid tumours by immune cells with anti-tumour activity is both a strong prognostic factor and a therapeutic goal. Recent approaches and applications of new technologies, especially single-cell mRNA analysis in dissecting tumour microenvironments have brought important insights into the biology of tumour-infiltrating immune cells, revealed a remarkable degree of cellular heterogeneity and distinct patterns of immune response. In this review, we will discuss recent advances in the understanding of tumour infiltrated lymphocytes, their prognostic benefit, and predictive value for immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.